- Home
- NXL vs RANI Comparison
NXL vs RANI Comparison
Compare NXL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- RANI
- Stock Information
- Founded
- NXL 2010
- RANI 2012
- Country
- NXL United States
- RANI United States
- Employees
- NXL N/A
- RANI N/A
- Industry
- NXL Medical Specialities
- RANI Medicinal Chemicals and Botanical Products
- Sector
- NXL Health Care
- RANI Health Care
- Exchange
- NXL Nasdaq
- RANI Nasdaq
- Market Cap
- NXL 21.0M
- RANI 17.0M
- IPO Year
- NXL 2022
- RANI 2021
- Fundamental
- Price
- NXL $0.95
- RANI $0.54
- Analyst Decision
- NXL Strong Buy
- RANI Strong Buy
- Analyst Count
- NXL 1
- RANI 4
- Target Price
- NXL $5.00
- RANI $7.75
- AVG Volume (30 Days)
- NXL 87.1K
- RANI 323.8K
- Earning Date
- NXL 08-07-2025
- RANI 08-05-2025
- Dividend Yield
- NXL N/A
- RANI N/A
- EPS Growth
- NXL N/A
- RANI N/A
- EPS
- NXL N/A
- RANI N/A
- Revenue
- NXL $131,065.00
- RANI $1,200,000.00
- Revenue This Year
- NXL $79.59
- RANI N/A
- Revenue Next Year
- NXL $334.65
- RANI N/A
- P/E Ratio
- NXL N/A
- RANI N/A
- Revenue Growth
- NXL N/A
- RANI N/A
- 52 Week Low
- NXL $0.59
- RANI $0.46
- 52 Week High
- NXL $4.49
- RANI $4.19
- Technical
- Relative Strength Index (RSI)
- NXL 30.94
- RANI 42.41
- Support Level
- NXL $0.89
- RANI $0.50
- Resistance Level
- NXL $1.03
- RANI $0.56
- Average True Range (ATR)
- NXL 0.08
- RANI 0.03
- MACD
- NXL -0.00
- RANI 0.02
- Stochastic Oscillator
- NXL 18.75
- RANI 42.87
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.